Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MS

The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.

Source link

Related posts

Reader response: Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders


Pre-clinical pilot study shows promising results of ‘concussion pill’


Resident & Fellow Rounds


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World